Nii Addy

Last updated
Nii Antie Addy
Alma mater Duke University (BA)
Yale University (PhD)
Scientific career
Institutions Yale School of Medicine
Thesis Role of calcineurin in nicotine-mediated behavior and signaling  (2007)

Nii Addy is an American neuroscientist who is an Associate Professor of Psychiatry at the Yale School of Medicine. His research considers the neurobiological basis of substance use disorders, depression, and anxiety. He has worked on various initiatives to mitigate tobacco use and addiction.

Contents

Early life and education

Addy earned his bachelor's degree at Duke University in 2000. [1] [2] He moved to Yale University for his doctoral studies, and graduated in 2010. [1] [3]

Research and career

After earning his doctoral degree Addy was appointed to the faculty at the Yale School of Medicine. [3] At Yale School of Medicine Addy leads a laboratory investigating the mechanisms of reinforcement learning and motivational control. [4] He has investigated the impact of vaping on teenager's brains. [5]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Nicotine</span> Mild chemical stimulant naturally found in some plants

Nicotine is a naturally produced alkaloid in the nightshade family of plants and is widely used recreationally as a stimulant and anxiolytic. As a pharmaceutical drug, it is used for smoking cessation to relieve withdrawal symptoms. Nicotine acts as a receptor agonist at most nicotinic acetylcholine receptors (nAChRs), except at two nicotinic receptor subunits where it acts as a receptor antagonist.

Hypersexuality is extremely frequent or suddenly increased libido. It is controversial whether it should be included as a clinical diagnosis used by mental healthcare professionals. Nymphomania and satyriasis were terms previously used for the condition in women and men, respectively.

Self-medication is a human behavior in which an individual uses a substance or any exogenous influence to self-administer treatment for physical or psychological ailments.

Psychomotor agitation is a symptom in various disorders and health conditions. It is characterized by unintentional and purposeless motions and restlessness, often but not always accompanied by emotional distress. Typical manifestations include pacing around, wringing of the hands, uncontrolled tongue movement, pulling off clothing and putting it back on, and other similar actions. In more severe cases, the motions may become harmful to the individual, and may involve things such as ripping, tearing, or chewing at the skin around one's fingernails, lips, or other body parts to the point of bleeding. Psychomotor agitation is typically found in major depressive disorder or obsessive-compulsive disorder, and sometimes the manic phase in bipolar disorder, though it can also be a result of an excess intake of stimulants. It can also be caused by severe hyponatremia. The middle-aged and the elderly are more at risk to express it.

Sensitization is a non-associative learning process in which repeated administration of a stimulus results in the progressive amplification of a response. Sensitization often is characterized by an enhancement of response to a whole class of stimuli in addition to the one that is repeated. For example, repetition of a painful stimulus may make one more responsive to a loud noise.

Septal area Area in the lower, posterior part of the medial surface of the frontal lobe

The septal area, consisting of the lateral septum and medial septum, is an area in the lower, posterior part of the medial surface of the frontal lobe, and refers to the nearby septum pellucidum.

Kynurenic acid Chemical compound

Kynurenic acid is a product of the normal metabolism of amino acid L-tryptophan. It has been shown that kynurenic acid possesses neuroactive activity. It acts as an antiexcitotoxic and anticonvulsant, most likely through acting as an antagonist at excitatory amino acid receptors. Because of this activity, it may influence important neurophysiological and neuropathological processes. As a result, kynurenic acid has been considered for use in therapy in certain neurobiological disorders. Conversely, increased levels of kynurenic acid have also been linked to certain pathological conditions.

Electronic cigarette Device that vaporizes a liquid nicotine solution for inhalation

An electronic cigarette is an electronic device that simulates tobacco smoking. It consists of an atomizer, a power source such as a battery, and a container such as a cartridge or tank. Instead of smoke, the user inhales vapor. As such, using an e-cigarette is often called "vaping". The atomizer is a heating element that atomizes a liquid solution called e-liquid. E-cigarettes are activated by taking a puff or pressing a button. Some look like traditional cigarettes, and most versions are reusable.

Nicotine dependence Chronic disease

Nicotine dependence is a state of dependence upon nicotine. Nicotine dependence is a chronic, relapsing disease defined as a compulsive craving to use the drug, despite social consequences, loss of control over drug intake, and emergence of withdrawal symptoms. Tolerance is another component of drug dependence. Nicotine dependence develops over time as a person continues to use nicotine. The most commonly used tobacco product is cigarettes, but all forms of tobacco use and e-cigarette use can cause dependence. Nicotine dependence is a serious public health problem because it leads to continued tobacco use, which is one of the leading preventable causes of death worldwide, causing more than 8 million deaths per year.

TA-CD is an active vaccine developed by the Xenova Group which is used to negate the effects of cocaine, making it suitable for use in treatment of addiction. It is created by combining norcocaine with inactivated cholera toxin.

Dennis S. Charney American medical researcher

Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

<span class="mw-page-title-main">Addiction</span> Disease resulting in compulsive engagement in rewarding stimuli despite adverse consequences

Addiction is a neuropsychological disorder characterized by a persistent and intense urge to use a drug, despite substantial harm and other negative consequences. Repetitive drug use often alters brain function in ways that perpetuate craving, and weakens self-control. This phenomenon – drugs reshaping brain function – has led to an understanding of addiction as a brain disorder with a complex variety of psychosocial as well as neurobiological factors that are implicated in addiction's development. Classic signs of addiction include compulsive engagement in rewarding stimuli, preoccupation with substances or behavior, and continued use despite negative consequences. Habits and patterns associated with addiction are typically characterized by immediate gratification, coupled with delayed deleterious effects.

Mark S. Gold

Mark S. Gold is an American physician, professor, author, and researcher on the effects of opioids, cocaine, tobacco, and other drugs as well as food on the brain and behavior. He is married to Janice Finn Gold.

Carolyn M. Mazure is an American psychologist and the Norma Weinberg Spungen and Joan Lebson Bildner Professor of Psychiatry and Psychology at the Yale School of Medicine. She created and directs Women’s Health Research at Yale — Yale’s interdisciplinary research center on health and gender.

Jed Eugene Rose, Ph.D. is an American academic professor, inventor and researcher in the field of nicotine and smoking cessation. Rose is presently the President and CEO of the Rose Research Center, LLC in Raleigh, North Carolina. Additionally, he is the Director of the Duke Center for Smoking Cessation at Duke University Medical Center.

Evolutionary models of drug use seek to explain human drug usage from the perspective of evolutionary fitness. Plants for instance, may provide fitness benefits by relieving pain. Proponents of this model of drug use suggest that the consumption of pharmacological substances for medicinal purposes evolved in the backdrop of human-plant coevolution as a means of self-medication. Humans thus learned to ignore the cues of plant toxicity because ingesting the bioactive compounds of plants in small amounts was therapeutic.

Marina Picciotto American neuroscientist

Marina Rachel Picciotto is an American neuroscientist known for her work on the role of nicotine in addiction, memory, and reward behaviors. She is the Charles B. G. Murphy Professor of Psychiatry and professor in the Child Study Center and the Departments of Neuroscience and of Pharmacology at the Yale University School of Medicine. Since 2015, she has been editor-in-chief of the Journal of Neuroscience.

Judson A. Brewer American psychiatrist, neuroscientist and author

Judson Alyn Brewer, M.D., Ph.D., is an American psychiatrist, neuroscientist and New York Times best-selling author. He studies the neural mechanisms of mindfulness using standard and real-time fMRI, and has translated research findings into programs to treat addictions. Brewer founded MindSciences, Inc., an app-based digital therapeutic treatment program for anxiety, overeating, and smoking. He is director of research and innovation at Brown University's Mindfulness Center and associate professor in behavioral and social sciences in the Brown School of Public Health, and in psychiatry at Brown's Warren Alpert Medical School.

Usage of electronic cigarettes Overview about the usage of electronic cigarettes

The usage of electronic cigarettes has risen rapidly since their introduction to the market in 2002. The global number of adult e-cigarettes users rose from about 7 million in 2011 to 68 million 2021 and 82 million in 2021. Awareness and use of e-cigarettes greatly increased over the few years leading up to 2014, particularly among young people and women in some parts of the world. Since their introduction vaping has increased in the majority of high-income countries. E-cigarette use in the US and Europe is higher than in other countries, except for China which has the greatest number of e-cigarette users. Growth in the UK as of January 2018 had reportedly slowed since 2013. The growing frequency of e-cigarette use may be due to heavy promotion in youth-driven media channels, their low cost, and the belief that e-cigarettes are safer than traditional cigarettes, according to a 2016 review. E-cigarette use may also be increasing due to the consensus among several scientific organizations that e-cigarettes are safer compared to combustible tobacco products. E-cigarette use also appears to be increasing at the same time as a rapid decrease in cigarette use in many countries, suggesting that e-cigarettes may be displacing traditional cigarettes.

Exposure to nicotine, from conventional or electronic cigarettes during adolescence can impair the developing human brain. E-cigarette use is recognized as a substantial threat to adolescent behavioral health. The use of tobacco products, no matter what type, is almost always started and established during adolescence when the developing brain is most vulnerable to nicotine addiction. Young people's brains build synapses faster than adult brains. Because addiction is a form of learning, adolescents can get addicted more easily than adults. The nicotine in e-cigarettes can also prime the adolescent brain for addiction to other drugs such as cocaine. Exposure to nicotine and its great risk of developing an addiction, are areas of significant concern.

References

  1. 1 2 "Nii Addy, PhD". Yale School of Medicine. Retrieved 2020-05-31.
  2. "Veritas Forum". www.christianityandscholarship.org. Retrieved 2020-05-31.
  3. 1 2 "Psychiatry Grand Rounds: "Dopaminergic Regulation of Motivated Behavior: Insight into the Neurobiological Bases of Substance Abuse and Mood Disorders" | Duke School of Medicine". medschool.duke.edu. Retrieved 2020-05-31.
  4. "Addy Lab". Addy Lab. Retrieved 2020-05-31.
  5. "How Vaping Nicotine Can Affect A Teenage Brain". NPR.org. Retrieved 2020-05-31.